The US Food and Drug Administration approved 50 new molecular entities in 2024 —just five fewer than it did in 2023. Last ...

Novo Nordisk's U.S.-listed and domestic shares rose Wednesday after analysts from UBS upgraded the Danish drugmaker's stock ...

Novo Nordisk has reported phase 3 results with its concizumab drug for haemophilia A or B, showing efficacy in the prevention of bleeding events that will support regulatory filings starting later ...

Novo Nordisk expands collaboration with Valo Health for cardiometabolic drugs and partners with Variant Bio on metabolic ...

Novo Nordisk's anti-TFPI antibody concizumab has been backed for approval in the EU as a once-daily drug to prevent bleeding episodes in people with haemophilia. The recommendation by the EMA's ...

Denmark-based pharma giant Novo Nordisk has announced plans to invest ... The company’s haemophilia portfolio includes Alhemo (concizumab) and its antibody asset Mim8, with the Phase III ...

With Alhemo (concizumab-mtci) from Novo Nordisk A/S, a third hemophilia drug in the past eight months has been approved by the U.S. FDA. The once-daily injectable prophylaxis is to prevent or reduce ...

The U.S. FDA has approved Alhemo, given as once-daily injections, to help prevent bleeds in patients with hemophilia A or B ...

Looking to expand its legacy in metabolic conditions, Novo Nordisk has inked a multiyear research pact with Variant Bio to better understand the genetics underlying disease across diverse populatio | ...